Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Second Quarter of 2007.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c69370) has announced the addition of new Decision Resources report Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Second Quarter of 2007 to their offering. Following considerable political activity in drug pricing and reimbursement in the world's major pharmaceutical markets in the first three months of 2007, the second quarter of the year proved to be relatively quiet. In the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. , Medicare Part D's growing share of the U.S. prescription drug prescription drug Prescription medication Pharmacology An FDA-approved drug which must, by federal law or regulation, be dispensed only pursuant to a prescription–eg, finished dose form and active ingredients subject to the provisos of the Federal Food, Drug, market could be bad news for pharmaceutical companies because employer-sponsored health plans typically offer more generous drug benefit designs. The French government's pharmaceutical cost-containment strategies--particularly its vigorous promotion of generics--yielded significant savings. German physicians, pharmacists, and patients struggled to adjust to new manufacturer rebate contracts in the generics market. In Italy, a government-imposed price cut reduced pharmaceutical spending in the first four months of 2007. Spain's new reference pricing system Noun 1. pricing system - a system for setting prices on goods or services system - a procedure or process for obtaining an objective; "they had to devise a system that did not depend on cooperation" immediately boosted reference-priced drugs' share of the pharmaceutical market. In the United Kingdom, a Parliamentary inquiry into the activity of the National Institute for Health and Clinical Excellence “NICE” redirects here. For other uses, see NICE (disambiguation). The National Institute for Health and Clinical Excellence or NICE is a Special Health Authority of the National Health Service in England and Wales. (NICE) uncovered serious concerns among drug manufacturers about the institute's impact on the heath care system domestically and abroad. Following the Japanese government's announcement that it was considering an overhaul of its drug pricing and reimbursement system in fiscal year 2008, the pharmaceutical industry prepared its proposals for reform. Get the Answers You Need to Shape Your Strategy - According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. Wolters Kluwer Wolters Kluwer N.V. (Euronext: WKL) is a leading global information services and publishing company. The company provides products and services for professionals in the health, tax, accounting, corporate, financial services, legal and regulatory, and education sectors. Health, 4.2 million U.S. Medicare beneficiaries--32% of all beneficiaries who had standard eligibility for coverage--fell into the Medicare coverage "gap" in 2006. What is the current trend in the number of health care plans offering coverage of drugs in the gap? - In June 2007, the U.S. Senate passed the Biologics Price Competition and Innovation Act. This act would afford manufacturers of innovative biologics 12 years of market exclusivity from the time of licensing and would create a procedure for the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. to approve biosimilar agents that are interchangeable with marketed products. What is the likelihood that the U.S. Congress will pass the bill, and what concerns about the bill has the Bush administration expressed? - The first rebate contracts between statutory health insurance funds and generics manufacturers in Germany took effect on April 1, 2007. By the beginning of June, 244 statutory health insurance funds had signed such contracts for almost 16,000 different product presentations of off-patent compounds. What challenges has the new system introduced for physicians, pharmacists, and patients? Why are small generics companies being particularly hurt by the new contracts? - Far from being content with the recent vigorous growth in the French generics market, the French government continues to set aggressive targets for generics dispensing. What is the overall generics dispensing rate the government has targeted for December 2007? Is this target attainable? - In May 2007, the U.K. House of Commons House of Commons: see Parliament. Select Committee on Health published written submissions it had received from interested parties regarding its inquiry into the activities of the National Institute for Health and Clinical Excellence (NICE). What criticisms and concerns did the pharmaceutical industry express about NICE? What specific recommendations did Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were offer regarding factors NICE should take into account during its drug appraisal process? - In June 2007, Janssen-Cilag offered the U.K. National Health Service a groundbreaking "moneyback guarantee" for coverage of Velcade. Industry observers believe that the NHS NHS abbr. National Health Service NHS (in Britain) National Health Service and other health care systems around the world may in future exert pressure on other manufacturers to sign similar risk-sharing agreements for high-priced drugs. What are the preliminary terms of the Velcade agreement? What terms have yet to be worked out? Scope - United States: Medicare Part D's growing share of prescription benefits; setbacks for government price negotiations for Medicare Part D; change in PDPs' coverage in the Medicare gap; relaxation of formulary formulary /for·mu·lary/ (for´mu-lar?e) a collection of recipes, formulas, and prescriptions. National Formulary see under N. for·mu·lar·y n. requirements; new employer-sponsored health plans for early retirees; Congressional debate on the Biologics Price Competition and Innovation Act; the U.S. judiciary's ruling on the Plavix patent dispute; convictions of Astra-Zeneca, Bristol-Myers Squibb, and Schering-Plough on overcharging. - European Union European Union (EU), name given since the ratification (Nov., 1993) of the Treaty of European Union, or Maastricht Treaty, to the European Community : Second Progress Report from the High-Level Pharmaceutical Forum; recommendations from the working group on the relative effectiveness of medicines. - France: Slowdown in the French pharmaceutical market; the French government's new cost containment cost containment, n the features of a dental benefits program or of the administration of the program designed to reduce or eliminate certain charges to the plan. drive. - Germany: Introduction of health economic evaluation for some new drugs; increasing demand for co payment-exempt medicines; implementation of a new system of rebate contracts between statutory health insurance funds and generics manufacturers; physician views on cost-containment; survey results regarding the under use of medicines in the German health care system. - Italy: Effect of the October 2006 price cuts on growth in the Italian pharmaceutical market. - Spain: Effects of Spain's new reference pricing system; the Spanish generics market; accelerated reimbursement decision making at the Spanish Ministry of Health. - Great Britain Great Britain, officially United Kingdom of Great Britain and Northern Ireland, constitutional monarchy (2005 est. pop. 60,441,000), 94,226 sq mi (244,044 sq km), on the British Isles, off W Europe. The country is often referred to simply as Britain. : Industry submissions regarding the House of Commons' review of NICE; the National Audit Office's review of primary care prescribing costs; NICE's preliminary support of Janssen-Cilag's "money-back guarantee" for Velcade. - Japan: Proposals for reform of the pricing and reimbursement system; the potential for growth in the Japanese generics market. - Outlook: Overall U.S. prescription sales in the face of rapid increase in Medicare pharmaceutical spending; opportunities and challenges in the face of employers' increasing use of value-based health benefit designs; implications for pharmaceutical manufacturers and drug prices of the European Union's High-Level Pharmaceutical Forum; intensification of reference prices in Germany, Spain, and France; growth of the generics market in France, Spain, and Japan. Content Outline: Executive Summary Strategic Considerations Stakeholder Implications Introduction United States Medicare Prescription Drug Benefit Growing Share of US Pharmaceutical Market Setback for Government Price Negotiations for Medicare Part D Millions Fall into Coverage Gap Relaxation of Formulary Requirements New Employer-Sponsored Health Plan for Early Retirees Employers Embrace Value-Based Health Benefits Biologics Price Competition and Innovation Act Plavix Patent Upheld Three Drug Manufacturers Convicted of Overcharging European Union Slow Progress for High-Level Pharmaceutical Forum France Slowdown in the French Pharmaceutical Market New Cost-Containment Drive Germany Health Economic Evaluation of New Drugs Increasing Demand for Co payment-Exempt Medicines Growth of Manufacturer Rebates Physician Concerns About Cost-Containment Under treatment of Key Disorders Italy Price Cuts Hit Sales Spain Rapid Increase in Market Share of Reference-Priced Drugs Sustained Growth of the Generics Market Faster Reimbursement Decision Making United Kingdom Parliamentary Review of NICE Review of Primary Care Prescribing Costs Janssen-Cilag "Money-Back Guarantee" Earns Backing of NICE Japan Proposals for Reform of the Pricing and Reimbursement System Growth Potential in the Generics Market Outlook and Implications for the Pharmaceutical Industry Tables and Figures Companies Mentioned: - Aetna - American Pharmaceutical Group - Amgen - Apotex - Association of the British Pharmaceutical Industry The Association of the British Pharmaceutical Industry (ABPI) is the trade association for companies in the UK producing prescription medicines. This is the British equivalent of PhRMA, however the member companies research, develop, manufacture and supply medicines prescribed - AstraZeneca - Bioindustry Association - Bristol-Myers Squibb - Eli Lilly Eli Lilly can refer to:
- European Federation of Pharmaceutical Industries and Associations The European Federation of Pharmaceutical Industries and Associations or EFPIA is the organization representing the research-based pharmaceutical industry operating in Europe. - Farmindustria - GlaxoSmithKline - Health Research and Educational Trust - Hewitt Associates Some of the information in this article may not be verified by . It should be checked for inaccuracies and modified to cite reliable sources. Hewitt Associates - High-Level Pharmaceutical Forum - HR Policy Association - Humana - Japan Pharmaceutical Manufacturers Association The Japan Pharmaceutical Manufacturers Association or JPMA is the organization representing the research-based pharmaceutical industry operating in Japan. The JPMA has 74 members including 20 overseas affiliates (as of October 1, 2006). - Johnson & Johnson - Kaiser Family Foundation The Henry J. Kaiser Family Foundation (KFF), or just Kaiser Family Foundation, is a U.S.-based non-profit, private operating foundation headquartered in Menlo Park, California. - Mercer Human Resource Consulting Mercer Human Resource Consulting is a human resource consulting firm that publishes the oft-quoted "Worldwide Cost of Living Survey." External links
- Merck Serono - Midwest Business Group on Health - National Federation of Italian Pharmacy Owners - Novartis - Pfizer - Roche - Sanofi-Aventis - Sawai Pharmaceuticals - Schering Health Care - Schering-Plough - Servier - Sierra Health Services health services Managed care The benefits covered under a health contract - U.S. Pharmacopeial phar·ma·co·pe·ial adj. 1. Of or relating to a pharmacopoeia. 2. Relating to a drug in the list of the United States Pharmacopoeia or similar pharmacopoeia. Convention - Wyeth For more information visit http://www.researchandmarkets.com/reports/c69370 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion